Navigation Links
Biocept and Clarient Announce Collaboration on First Test for Circulating Tumor Cells and HER2 Status in Breast Cancer Patients
Date:8/24/2011

associated instrumentation, an antibody capture cocktail, and CEE-Enhanced™ staining technology, with biomarker assays being performed on CTCs captured in the channels.

About OncoCEE™

The OncoCEE™ platform, developed by Biocept, has demonstrated that it can consistently and accurately capture extremely rare cells from blood, like CTCs, which may be present in only 1 of every 50-100 billion blood cells. Biocept obtains patient samples via a simple blood draw, or "liquid biopsy", instead of relying on traditional biopsy methods or surgical procedures.  Biocept differentiates its "liquid biopsy" CTC analysis by combining CTC enumeration and diagnostic (e.g., HER2 status) biomarker analyses, information not currently available through commercial laboratories using existing technologies for CTC testing.  Other methods to capture, detect and enumerate CTCs rely only on the expression of the epithelial cell adhesion (EpCAM) molecule and cytokeratins, and do not include molecular biomarker analysis.  This approach may exclude CTCs that have undergone intrinsic modifications of their phenotype, such as the epithelial-to-mesenchymal transition (EMT).   EMT may represent a possible explanation for many patients who, despite an aggressive disease, are found negative for the presence of CTCs.  OncoCEE™ captures epithelial (i.e., EpCAM positive) CTCs and mesenchymal-like CTCs.  Additionally, the OncoCEE™ platform enables evaluation of diagnostic biomarkers by techniques like immunocytochemistry, fluorescence in situ hybridization (FISH) and mutation analysis.  An example is HER2 status, which Biocept determines by FISH.  HER2 status is diagnostic of a potential response to HER2-targeted agents such as Herceptin® and Tykerb®.


'/>"/>
SOURCE Biocept, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Biocept, Inc. Announces CEO and Director Appointments
2. Biocept, Inc. Announces Two New Director Appointments
3. Biocept, Inc. Announces New Director Appointment - September 28, 2010
4. Biocept Demonstrates Multiple Phenotypes of Circulating Tumor Cells (CTCs) in Cancer Patients
5. Biocept, Inc. Announces New CFO
6. Biocept, Inc. Announces Availability of Its New Breast Cancer Test, OncoCEE-BR™ Utilizing Circulating Tumor Cells (CTCs)
7. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
8. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
9. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
10. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
11. Clarient to Present at Noble Financials 5th Annual Equity Conference on Tuesday, June 9th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... (PRWEB) December 19, 2014 BioPlus ... specialty pharmacies, announces the promotion of Nick Maroulis, Pharm.D. ... Specialty Pharmacy Services. , In this position, Dr. ... while also managing the directors of our multi-site pharmacies ... BioPlus since 1997 and during that time he has ...
(Date:12/19/2014)... REDWOOD CITY, Calif. , Dec. 19, 2014 ... , USA) announced today that they have been ... Technologies 1,2 is a privately held company that ... processing of next generation sequencing (NGS) data for the ... into the Roche Sequencing Unit, and will continue to ...
(Date:12/19/2014)... 18, 2014 BioPlus Specialty ... specialty pharmacies, has an expanded team of Regional ... consultants for prescriber offices in their regions, with ... “We have a variety of Regional Pharmaceutical Care ... specializing in hepatitis C help prescribers understand all ...
(Date:12/19/2014)... ME (PRWEB) December 18, 2014 Ed ... director of the Center for Excellence in the Neurosciences ... New England, has been selected as a member of ... is the first neuroscientist from Maine to receive this ... nonprofit organization supported entirely by the Dana Foundation. ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3
... Inc.,(Nasdaq: BNVI ) today announced the online ... Menerba(TM) (formerly MF101) is,well tolerated, safe and effective for ... associated with menopause. , The ... safety and,efficacy of two doses of Menerba versus placebo. ...
... be involved in Asia Pacific,s largest homeland security Conference and Exhibition. ... ... largest and most comprehensive homeland security and counter terrorism Conference and ... Singapore from 17th to 19th March. The event will showcase ...
... shapes such as a crane or a butterfly is ... fold something that,s about a hundred times thinner than ... as an electronic device. , A team of ... engineering, is developing the basic principles of nano-origami, a ...
Cached Biology Technology:Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM) 2Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM) 3Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM) 4News Release: Homeland Security to Take Centre Stage with Global Security Asia 2009 2News Release: Homeland Security to Take Centre Stage with Global Security Asia 2009 3MIT uses nano-origami to build tiny electronic devices 2MIT uses nano-origami to build tiny electronic devices 3
(Date:12/17/2014)... 2014  HITLAB SM announced today its ... to confirm its adherence to current U.S. Food ... HITLAB to conduct regulated smart device and smart ... patient safety and research quality. "HITLAB ... and delivery with innovative technology," said Laura ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) ... Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used ... measures the overall facial feature of a person ... distance between eyes. Facial recognition is used for ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3New telemetry implants expected to change how large animal toxicology studies are conducted 2
... Institute have identified a set of previously unknown mutations ... tumors of the nervous system that occur in young ... childhood cancer deaths. The discovery is intriguing because ... carrying two of the mutations to die when treated ...
... confirmed: Even though flatback turtles dine on fish, ... primarily herbivorous green sea turtles. New genetic research ... Scientist at the Center for Biodiversity and Conservation ... colleagues clarifies our understanding of the evolutionary relationships ...
... study(1) published in the November issue of a scientific journal, ... on behalf of the Society of Toxicology, describes the kidney ... was done to characterize the toxicity of the compounds that ... research points to a possible link between the pet food ...
Cached Biology News:Researchers identify promising gene target for neuroblastoma therapy 2Revealing the evolutionary history of threatened sea turtles 2
Tight junctions are complexes of proteins that create intercellular boundaries between the plasma membrane domains of epithelial and endothelial cells. Antigen: Synthetic peptide corresponding to...
Polyclonal Antibody to TRIB1/ SKIP1/ Tribbles 1...
TNF-Related Apoptosis Inducing Ligand-Receptor-1...
PMA (YPMA-1)...
Biology Products: